Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SLL (Small Lymphocytic Lymphoma): early-phase trial registry
1 of 2 indexed SLL (Small Lymphocytic Lymphoma) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
SLL (Small Lymphocytic Lymphoma): 2 US clinical trials tracked, 1 recruiting.
SLL (Small Lymphocytic Lymphoma) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Lomond Therapeutics Holdings, running 1 of these trials.
Enrollment posture brief
Registry condition sll-small-lymphocytic-lymphoma
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
SLL (Small Lymphocytic Lymphoma) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for SLL (Small Lymphocytic Lymphoma) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
SLL (Small Lymphocytic Lymphoma) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings
NCT06708897
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT01500733
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on SLL (Small Lymphocytic Lymphoma) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on SLL (Small Lymphocytic Lymphoma) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this SLL (Small Lymphocytic Lymphoma) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 SLL (Small Lymphocytic Lymphoma) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lomond Therapeutics Holdings sponsors the most SLL (Small Lymphocytic Lymphoma) trials on record, review their full trial history before evaluating a specific study. See Lomond Therapeutics Holdings's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SLL (Small Lymphocytic Lymphoma) condition card totals 2 registered trials; most-linked intervention PCI 32765; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.